 |
 |
| [2000.6.24 Hamamatsu Act City] |
|
S-9-1;
Some observations on the structure and
function of heparan sulphate
|
John T Gallagher,
Paterson Institute, Manchester M20 4BX, England |
|
S-9-2;
Syndecan-4 deficiency impairs the fetal
vessels in the placental labyrinth.
|
K. Ishiguro, T. Kojima
Nagoya University, School of Medicine and Nagoya University, School
of Health Sciences, Nagoya, Japan |
|
S-9-3;
Heparanase Expression in Metastatic
Tumors
|
Motowo Nakajima
Tsukuba Research Institute, Novartis Pharma K.K. Ibaraki, Japan
|
|
S-9-4;
The possible role of PG-M/versican
in human coronary restenosis after angioplasity
|
K. Imanaka-Yoshida
and T. Yoshida
Department of Pathology, Mie University School of Medicine, Tsu,
514-8507, Japan |
|
S-9-5;
Proteoglycans (PGs) in the infarcted
and the pressure-overloaded hearts.
|
T. Murakami1, S. Kusachi1,
Y. Ninomiya2, T. Tsuji1
1Depertment of Internal Medicine I and 2Depertment of Molecular
Biology and Biochemistry, Okayama University Medical School, Okayama,
700-8558, Japan |
|
S-9-6;
The Role of Proteoglycans and Hyaluronan
in Atherosclerosis and Restenosis.
|
Thomas N. Wight,
Ph.D., Department of Pathology, University of Washington, Seattle,
WA 98195 |
|
|
S-9-7;
Regulation of proteoglycan synthesis
mediated by thrombin receptor in human coronary endothelial
cells in culture
|
|
1T. Kaji, 1C. Yamamoto, 2M.G.
Kinsella and 2T. N. Wight
1Department of Environmental Health, Faculty of Pharmaceutical
Sciences, Hokuriku University, Kanazawa, Japan, 2Department of
Pathology, School of Medicine, University of Washington, Seattle,
USA
|
|
|
S-9-8;
Physiological function of extracellular-superoxide
dismutase and reduction of its heparin-affinity by arginine-213
to glycine mutation
|
|
T. Adachi
Laboratory of Clinical Pharmaceutics, Gifu Pharmaceutical University,
Gifu, 502-8585, Japan
|
|
|
S-9-9;
Heparin and angiogenic therapy
|
|
M. Fujita
College of Medical Technology, Kyoto University, Kyoto, Japan
|
|
|
S-9-10;
Synthetic and biotechnology derived
glycomimetics. Impact on drug development.
|
|
J. Fareed,
Loyola University Medical Center, Maywood, IL USA
|
|
|
S-9-11;
Proteoglycans as biomaterials
|
|
Takehisa Matsuda
Dept. Biomedicalengineering, Graduate School of Medicine, Kyushu
University, Maidashi 3-1-1, Higashi-ku, Fukuoka 812-8582, JAPAN
|
|
|
S-9-12;
Dermatan sulfate enhances cellular
growth and differential production of various kinds of cell
growth factor by normal skin fibroblasts.
|
|
1Y.
Naito, 2Y. Takada, 3M.
Kyogashima, 3T. Sakai, 1H.
Sugimura, and 4A.Takada
1I st Department of Pathology,
2Department of Pathophysiology,
and 42nd Department of Physiology,
Hamamatsu University School of Medicine, hamamatsu, and 3Seikagaku
Corporation Tokyo Research Institute, Japan
|
|
|
S-9-13
Effect of topical application of
glycosaminoglycan in wound healing.
|
|
Y. Takae, S. Izaki, K. Kitamura,
Y. Hori, T. Sakai and M. Kyogashima.
Dermatology, Saitama Medical Center, Saitama Medical School, Kawagoe,
Japan and Seikagaku Corp., Tokyo Res. Inst., Tokyo, Japan.
|
|
|
S-9-14
Role of CD44 and proteoglycan in inflammatory
processes: in the context of cell adhesion
|
|
Y. Tanaka
The First Department of Internal Medicine, School of Medicine,
University of Occupational and Environmental Health, Japan, Kitakyushu
807-8555, Japan
|
|
|
| トップページへ戻る→
|
|
|